Patient safety guidance should include: Education about expected appetite changes and strategies for maintaining adequate nutrition Monitoring for excessive weight loss or signs of malnutrition Assessment of mental health at follow-up visits Clear instructions to report severe or persistent nausea, vomiting, or neuropsychiatric symptoms Awareness that cognitive effects remain investigational and should not influence prescribing decisions Reporting severe persistent abdominal pain (pancreatitis), right upper quadrant pain/jaundice (gallbladder disease), severe abdominal distension with inability to pass gas or stool (possible ileus), persistent vomiting or signs of dehydration, and new/worsening vision changes (retinopathy) Understanding increased hypoglycemia risk when combined with insulin or sulfonylureas GLP-1 receptor agonists are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and should be used with caution in patients with severe gastrointestinal disease, including gastroparesis

The rise of GLP-1 medications like Ozempic and Wegovy, which help regulate appetite and blood sugar, isn't just changing waistlines
The comparison between different GLP-1 medications shows they are not interchangeable without proper medical guidance
Those who are committed to a long-term approach to weight loss, with close monitoring and lifestyle changes
[21] Even most revealing: vitamin D status directly influences HMB's effectiveness
Diabetologia 59:13671371 Lao J, Hansen BC, Dimarchi R, Pocai A (2013) Effect of GLP1R/GCGR dual agonist in monkeys